Plain-English translation of NCT07594067 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This Phase 1 trial is testing —a new type of personalized cancer treatment made from your own immune cells. The cells are engineered in a lab to recognize and attack cancer cells that have a specific KRAS G12V genetic mutation. This treatment is being studied in patients with advanced pancreatic, bile duct, colorectal, or lung cancer.
Many patients with these types of cancer have exhausted standard treatment options like chemotherapy. This medication targets a specific genetic mutation found in many of these cancers, offering a new approach for patients who need more options.
You likely qualify if…
You likely don't qualify if…
You would undergo blood tests and scans to confirm you're eligible, then your own immune cells would be collected and sent to a lab to be engineered. After the cells are grown, you would receive an infusion of the treatment. The study will test different dose levels in small groups of patients, starting with lower doses and increasing if the treatment is safe. You will have regular follow-up visits to monitor for side effects and check whether the treatment is working.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
United States